Jingtian & Gongcheng assists pharmaceutical companies in their growth, innovation and development. It handles a considerable workload, including the traditional IP, M&A and joint ventures, as well as handling cooperative development and technology licensing, clinical trials and commercial transactions. Equity partner Boija Zhao has dedicated over a decade to the sector, advising on the entire life cycle of pharmaceuticals, from research and development to commercialisation. Siqi Fu focuses on overseas capital markets in the biotechnology and healthcare fields.
Legal 500 Editorial commentary
Accolades
Client satisfaction
Key clients
- China National Pharmaceutical Group Corporation
- Sinopharm Group Co., Ltd. No
- Shanghai Junshi Biosciences Co., Ltd Yes
- PKU HealthCare Corp., Ltd.
- Chiesi Pharmaceutical (Shanghai) Co. Ltd
- Zhejiang Intmedic Co., Ltd.
- Fujian Haixi Pharmaceuticals Co., Ltd.
- Jiangsu Quanxin Biopharmaceutical Co., Ltd. Qyuns Therapeutics Co., Ltd.
- Genfleet Therapeutics (Shanghai), Inc.
- Yafei (Shanghai) Biomedical Technology Co., Ltd.
Work highlights
Advised Hengrui Pharmaceuticals, a leader in the Chinese pharmaceutical industry, on its successful Hong Kong IPO and dual "A+H" listing. This marked the largest healthcare IPO on HKEX in five years.
Assisted Mirui Group to successfully go public in Hong Kong, which is the largest 18A IPO project in the field of medical devices.
Assisted Santian Pharmaceutical in reaching the world's first suprachoroidal injection therapy with Jimu Biotech ARVN001 carrying out commercial cooperation and technology licensing transactions.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Yuanpeng Lang
Other key lawyers
Boija Zhao; Siqi Fu; Hanshuo Zhou